Adaptive Biotechnologies Corp (ADPT)

$13.39 +0.07 (0.53%)
Market Cap 2.03B
Revenue (ttm) 276.98M
Net Income (ttm) -59.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -21.48%
Debt to Equity Ratio 0.00
Volume 1,734,675
Avg Vol 2,067,776
Day's Range N/A - N/A
Shares Out 153.98M
Stochastic %K 27%
Beta 2.19
Analysts Strong Sell
Price Target $20.86

Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient'...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 659 0067
Fax: 206 659 0667
Address:
1165 Eastlake Avenue East, Seattle, United States
RunnerSignals
RunnerSignals Mar. 14 at 8:06 AM
$ADPT reclaiming momentum from $12.45 support. RSI 32 and volume 3.9M vs 2.0M avg. accumulation visible. outlook: positive
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 13 at 5:52 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
nickmick
nickmick Mar. 12 at 6:37 PM
$ADPT Accumulating! Solid business model, conservative guidance, take-over target, completely oversold. Ty!
1 · Reply
Treasury225
Treasury225 Mar. 12 at 6:15 PM
$ADPT ya gotta think if there is a stock that is immune to the escalating war issues it’s ADPT. Feels like the covid market… Sell everything and wait. The company is MUM so maybe there’s something more specific but this chart sucks.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 3 at 2:27 AM
$ADPT RSI: 53.27, MACD: -0.3197 Vol: 0.88, MA20: 16.21, MA50: 16.88 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 2 at 9:28 PM
$ADPT Current Stock Price: $16.11 Contracts to trade: $15.0 ADPT Mar 20 2026 Call Entry: $1.03 Exit: $1.48 ROI: 43% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
1AlwaysBull1
1AlwaysBull1 Mar. 2 at 8:37 PM
$ADPT i'm in for a swing
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 2 at 2:32 PM
$ADPT Share Price: $15.71 Contract Selected: Oct 16, 2026 $20 Calls Buy Zone: $1.99 – $2.46 Target Zone: $3.61 – $4.41 Potential Upside: 71% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Feb. 26 at 6:09 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
Joncook642
Joncook642 Feb. 25 at 2:07 PM
$ADPT Gonna be a good day for the whole market 😉
0 · Reply
Latest News on ADPT
Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript

Feb 6, 2026, 12:14 PM EST - 5 weeks ago

Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 5, 2026, 4:05 PM EST - 5 weeks ago

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Jan 27, 2026, 4:05 PM EST - 7 weeks ago

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

Jan 22, 2026, 4:05 PM EST - 7 weeks ago

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

Adaptive Biotechnologies Corporation (ADPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 10:35 PM EST - 2 months ago

Adaptive Biotechnologies Corporation (ADPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

Jan 12, 2026, 7:30 AM EST - 2 months ago

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

Adaptive Biotechnologies spinout raising $15M to develop clinical sequencing tech

Jan 6, 2026, 11:51 AM EST - 2 months ago

Adaptive Biotechnologies spinout raising $15M to develop clinical sequencing tech

Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 30, 2025, 4:05 PM EST - 2 months ago

Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million

Dec 15, 2025, 8:24 AM EST - 3 months ago

Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million

PFE

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

Dec 15, 2025, 8:00 AM EST - 3 months ago

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

PFE

Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

Dec 9, 2025, 5:07 PM EST - 3 months ago

Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Dec 6, 2025, 8:30 AM EST - 3 months ago

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?

Dec 5, 2025, 1:33 PM EST - 3 months ago

Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

Nov 24, 2025, 7:30 AM EST - 4 months ago

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

Adaptive Biotechnologies Corporation (ADPT) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:56 AM EST - 4 months ago

Adaptive Biotechnologies Corporation (ADPT) Q3 2025 Earnings Call Transcript

Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 4 months ago

Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results

Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 15, 2025, 4:05 PM EDT - 5 months ago

Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

Adaptive Biotechnologies Corporation (ADPT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 3:58 PM EDT - 6 months ago

Adaptive Biotechnologies Corporation (ADPT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 27, 2025, 4:05 PM EDT - 7 months ago

Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aristotle Focus Growth Q2 Highlights: Top Performers, Surprises And Strategic Shifts

Aug 8, 2025, 6:05 AM EDT - 7 months ago

Aristotle Focus Growth Q2 Highlights: Top Performers, Surprises And Strategic Shifts

ASPS

Adaptive Biotechnologies Corporation (ADPT) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 2:13 AM EDT - 7 months ago

Adaptive Biotechnologies Corporation (ADPT) Q2 2025 Earnings Call Transcript

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 4:05 PM EDT - 8 months ago

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025

Jul 15, 2025, 4:05 PM EDT - 8 months ago

Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

Jul 1, 2025, 7:30 AM EDT - 9 months ago

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

May 30, 2025, 7:30 AM EDT - 10 months ago

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 28, 2025, 4:05 PM EDT - 10 months ago

Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Adaptive Biotechnologies Corporation (ADPT) Q1 2025 Earnings Call Transcript

May 1, 2025, 9:46 PM EDT - 11 months ago

Adaptive Biotechnologies Corporation (ADPT) Q1 2025 Earnings Call Transcript

Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

May 1, 2025, 4:05 PM EDT - 11 months ago

Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

Apr 10, 2025, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

Adaptive Biotechnologies Corporation (ADPT) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 7:47 PM EST - 1 year ago

Adaptive Biotechnologies Corporation (ADPT) Q4 2024 Earnings Call Transcript

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

Jan 22, 2025, 4:05 PM EST - 1 year ago

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Jan 14, 2025, 7:30 AM EST - 1 year ago

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

Jan 7, 2025, 7:30 AM EST - 1 year ago

Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 4:05 PM EST - 1 year ago

Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

Dec 7, 2024, 6:30 PM EST - 1 year ago

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

Dec 3, 2024, 7:30 AM EST - 1 year ago

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

Adaptive Biotechnologies: Making Some Progress

Nov 26, 2024, 10:53 AM EST - 1 year ago

Adaptive Biotechnologies: Making Some Progress

Adaptive Biotechnologies Corporation (ADPT) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 9:57 PM EST - 1 year ago

Adaptive Biotechnologies Corporation (ADPT) Q3 2024 Earnings Call Transcript

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

Nov 7, 2024, 7:30 AM EST - 1 year ago

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

Oct 9, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

Aug 29, 2024, 7:30 AM EDT - 1 year ago

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 22, 2024, 4:03 PM EDT - 1 year ago

Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Adaptive Biotechnologies Corporation (ADPT) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 10:25 PM EDT - 1 year ago

Adaptive Biotechnologies Corporation (ADPT) Q2 2024 Earnings Call Transcript

Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results

Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024

Jul 11, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

May 31, 2024, 7:30 AM EDT - 1 year ago

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 29, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

RunnerSignals
RunnerSignals Mar. 14 at 8:06 AM
$ADPT reclaiming momentum from $12.45 support. RSI 32 and volume 3.9M vs 2.0M avg. accumulation visible. outlook: positive
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 13 at 5:52 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
nickmick
nickmick Mar. 12 at 6:37 PM
$ADPT Accumulating! Solid business model, conservative guidance, take-over target, completely oversold. Ty!
1 · Reply
Treasury225
Treasury225 Mar. 12 at 6:15 PM
$ADPT ya gotta think if there is a stock that is immune to the escalating war issues it’s ADPT. Feels like the covid market… Sell everything and wait. The company is MUM so maybe there’s something more specific but this chart sucks.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 3 at 2:27 AM
$ADPT RSI: 53.27, MACD: -0.3197 Vol: 0.88, MA20: 16.21, MA50: 16.88 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 2 at 9:28 PM
$ADPT Current Stock Price: $16.11 Contracts to trade: $15.0 ADPT Mar 20 2026 Call Entry: $1.03 Exit: $1.48 ROI: 43% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
1AlwaysBull1
1AlwaysBull1 Mar. 2 at 8:37 PM
$ADPT i'm in for a swing
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 2 at 2:32 PM
$ADPT Share Price: $15.71 Contract Selected: Oct 16, 2026 $20 Calls Buy Zone: $1.99 – $2.46 Target Zone: $3.61 – $4.41 Potential Upside: 71% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Feb. 26 at 6:09 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
Joncook642
Joncook642 Feb. 25 at 2:07 PM
$ADPT Gonna be a good day for the whole market 😉
0 · Reply
Joncook642
Joncook642 Feb. 18 at 2:06 PM
$ADPT Guidance is to low. Gonna beat for the next 3 quarters. I’m in now😉
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Feb. 14 at 4:31 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
50bps
50bps Feb. 6 at 6:59 PM
$ADPT what a forking
0 · Reply
Treasury225
Treasury225 Feb. 6 at 4:14 PM
$ADPT guidance way too conservative and the stock is being punished for it… bright side, IMO, beating guidance in each of the next four Q’s.
0 · Reply
erevnon
erevnon Feb. 6 at 11:49 AM
BTIG maintains Adaptive Biotechnologies $ADPT at Buy and raises the price target from $21 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 5 at 9:27 PM
$ADPT Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.09 up 60.87% YoY • Reported revenue of $71.68M up 51.04% YoY • Adaptive Biotechnologies projects 2026 full year MRD business revenue between $255M and $265M. Total company operating expenses, including cost of revenue, are expected to be $350M to $360M.
0 · Reply
G101SPM
G101SPM Feb. 4 at 8:38 PM
#SHOWTIME ASTCT and CIBMTR Tandem Meeting (February 5) Scheduled to appear: $ACLX, $ADPT, $ARTV, $XCUR Americas Committee for Treatment and Research in Multiple Sclerosis Forum (February 5-6) Scheduled to appear: $TGTX
0 · Reply
DavisDivergence
DavisDivergence Feb. 4 at 9:37 AM
$ADPT biotech, immuno-oncology platform
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Feb. 3 at 7:44 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
Treasury225
Treasury225 Jan. 22 at 9:28 PM
$ADPT pretty convincing breakout on the 15min and daily chart. Interesting volume, not big but….interesting
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jan. 22 at 1:31 AM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
Treasury225
Treasury225 Jan. 20 at 4:17 PM
$ADPT Greenlanders are loading up on this stock.
0 · Reply